How do drugs affect your mental health? The clinical perspective
Medically reviewed by Paul Hornsey
The interplay between psychoactive substances and mental health pathology remains one of the most clinically complex – and increasingly prevalent – presentations in modern psychiatry.
Despite frequent public discourse around “drug misuse” and “mental illness,” the nuanced relationship between these domains is often obscured by stigma1, misinformation2, and oversimplistic cause-effect narratives.
Across UK clinical settings, the incidence of comorbid substance use and mental health disorders – commonly referred to as dual diagnosis – has grown markedly. According to recent data, individuals presenting with psychiatric symptoms are significantly more likely to engage in high-risk substance use3, while those with substance use disorders are, in turn, at elevated risk of developing affective, psychotic, and neurocognitive conditions. The bidirectional nature of this relationship4 presents clear diagnostic and therapeutic challenges, particularly in cases involving subclinical pathology, complex trauma, or pharmacological polyexposure.
The relationship between substance use and mental health
The relationship between substance use and mental health is neither linear nor uniform. It is mediated by a wide constellation of biological, psychological, and social variables; ranging from genetic predisposition and neurodevelopmental profile to environmental adversity, cultural framing, and epigenetic expression.
Clinically, substance use may act as a precipitant, a perpetuating factor, a maladaptive coping mechanism, or – on occasion – a misguided attempt at self-regulation.
Causation, correlation, and clinical entanglement
Distinguishing causality from correlation is one of the central challenges in the assessment and management of comorbid substance use and psychiatric symptomatology5. Patients may present with depressive symptoms secondary to chronic alcohol misuse; equally, a primary affective disorder may drive the consumption of benzodiazepines or stimulants as a compensatory behaviour. In many cases, the two pathways operate simultaneously6.
Key considerations include:
Neurobiological overlap and shared circuitry
Multiple studies have established that substance use disorders and psychiatric conditions share common neurobiological substrates, particularly in relation to dopaminergic signalling7, prefrontal cortical dysregulation, and limbic system hyperactivation7. Chronic exposure to exogenous substances can alter neuroplasticity7, downregulate receptor sensitivity, and create enduring changes in reward processing and threat perception.
This is particularly relevant8 in:
Psychosocial risk factors and pathways to comorbidity
The emergence of comorbid mental health and substance use disorders9 is rarely attributable to a single vector. Instead, risk accrues cumulatively – through early adversity, chronic stress exposure, cultural silence around distress, and lack of appropriate intervention.
High-risk psychosocial pathways include:
The spectrum of clinical presentations
While some individuals may meet formal diagnostic thresholds for both a mental health disorder and a substance use disorder, many more sit within the grey zone of subthreshold or intermittent symptoms.
These cases are no less serious – and often represent a significant treatment challenge due to diagnostic ambiguity, fluctuating presentation, and ambivalence about engagement.
In clinical practice, the presentations encountered include:
How different types of drugs impact the brain and mood
Different substances exert markedly different neurochemical effects, each with distinct psychiatric implications. Some act primarily on dopaminergic and noradrenergic pathways, altering reward perception and arousal; others modulate GABAergic or glutamatergic systems, impacting inhibition, cognition, and mood regulation. A growing body of research also highlights the long-term alterations in brain structure10 and function that can result from both acute intoxication and chronic use.
While no two clinical presentations are identical, patterns do emerge based on the substance class, dosage, frequency of use, co-occurring conditions, and individual vulnerability. The table below outlines broad psychiatric profiles commonly associated with each substance group:
Psychiatric Effects of Common Drug Classes4, 7, 10, 11
Drug Class / Substance
Neurochemical Target(s)
Short-Term Psychiatric Effects
Long-Term Psychiatric Risks
Stimulants (e.g. cocaine, amphetamines, methamphetamine)
↑ Dopamine, ↑ Noradrenaline
Euphoria, increased energy, irritability, anxiety, insomnia, paranoia
Persistent anxiety, mood instability, psychosis, executive dysfunction
Depressants (e.g. alcohol, benzodiazepines, GHB)
↑ GABA, ↓ Glutamate
Disinhibition, sedation, emotional lability, depressive symptoms
Depression, memory impairment, suicidality, rebound anxiety, tolerance and dependence
Opioids (e.g. heroin, codeine, fentanyl, morphine)
μ-opioid receptors, ↓ Noradrenaline
Analgesia, euphoria, apathy, emotional blunting
Anhedonia, mood dysregulation, increased suicidality, cognitive dulling
Cannabis
CB1 receptor agonism, Dopamine modulation
Relaxation, altered perception, anxiety, depersonalisation
Psychosis (especially in younger users), amotivation, cognitive decline, exacerbation of mood disorders
Hallucinogens (e.g. LSD, psilocybin, mescaline)
5-HT2A agonism
Visual/auditory hallucinations, depersonalisation, euphoria or anxiety
Hallucinogen-persisting perception disorder (HPPD), mood destabilisation, anxiety syndromes
Dissociatives (e.g. ketamine, PCP, nitrous oxide)
NMDA antagonism, ↑ Dopamine
Detachment, confusion, altered body perception
Cognitive fragmentation, mood instability, psychotic symptoms
Synthetic/Novel Psychoactive Substances (NPS)
Variable; polypharmacological
Unpredictable; often a combination of stimulant, hallucinogenic, and dissociative effects
Seizures, persistent paranoia, psychosis, neurotoxicity
Subtleties and clinical caveats
That said, it’s important to emphasise that psychiatric outcomes depend on far more than pharmacological action. The same substance may function as a mood stabiliser in one client, a destabiliser in another. This is particularly evident in:
Clinicians should also be attuned to latent psychiatric conditions unmasked by substance use – particularly in younger adults. Cannabis-induced psychosis, for instance, may herald the emergence of a primary psychotic disorder11 in those with underlying genetic vulnerability.
Managing dual diagnosis: best practices and clinical considerations
The management of dual diagnosis – where substance use disorders and mental health conditions coexist12 – requires an integrated, multidisciplinary approach. Treating either condition in isolation risks incomplete recovery, premature relapse, or misdiagnosis. Yet in practice, fragmentation of services and rigid treatment pathways can often complicate care.
At a clinical level, best practice involves:
Dual diagnosis often demands more than standard care protocols. Many individuals require flexible, private, and deeply personalised pathways that reflect their clinical complexity and lived experience.
Final reflections and when to refer
Substance misuse and mental health conditions rarely occur in isolation14. For many individuals, they are entangled threads of the same clinical narrative15 – manifesting through mood instability, impaired functioning, and a quiet erosion of identity. Effective care requires more than identification; it demands nuance, timing, and trust.
For healthcare providers, the decision to refer hinges not only on symptom severity, but on clinical trajectory, insight, and capacity for engagement. Timely referral is especially indicated when:
At Harbor London, we specialise in high-complexity presentations that sit outside conventional systems – offering medically-led, discreet programmes for individuals requiring privacy, personalisation, and sustained psychiatric input. For more information or a confidential conversation, contact the Harbor London clinical team directly.
